Jeffrey J. Lochhead, PhD

Assistant Research Professor, Pharmacology

Contact Information

Office: 557
Building: Life Sciences North
Phone: (520) 626-7123

Email: lochhead@arizona.edu

  • BS: Northern Arizona University, 2000
  • PhD: University of Arizona, 2011
Research Area: 
Neuroscience and Pain
Research Interests: 

Inflammatory pain induced alterations in the blood-brain barrier including brain uptake of opioid drugs and paracellular permeability changes due to tight junction modifications. Mechanisms governing intranasal drug delivery to the CNS. Pathophysiological changes affecting intranasal drug delivery to the CNS.

 

Publications

2022

Regulation of Blood-Brain Barrier Transporters by Transforming Growth Factor-/Activin Receptor-Like Kinase 1 Signaling: Relevance to the Brain Disposition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (i.e., Statins).

High-Dose Acetaminophen Alters the Integrity of the Blood-Brain Barrier and Leads to Increased CNS Uptake of Codeine in Rats.

2020

Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders.

2017

Hypoxic Stress and Inflammatory Pain Disrupt Blood-Brain Barrier Tight Junctions: Implications for Drug Delivery to the Central Nervous System.

Anti-NMDA receptor encephalitis presenting as a primary psychotic disorder.

2016

Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery.

2015

Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration.

2012

Intranasal delivery of biologics to the central nervous system.

Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain.

2010

Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation.

2009

Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress.

2005

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.

Water Quality and Cholesterol-induced pathology: differential effects of the M-1 muscarinic receptor agaonist AF267b on accumulation of Alzheimer-like Amyloid B in rabbit brain

2002

Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid beta (Abeta) in rabbit brain.

2014

Intranasal drug delivery to the brain